Clinical Trial Update: Combination Therapy of HAIC, Surufatinib and Tislelizumab for Unresectable or Metastatic Biliary Tract Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial investigating a combination of hepatic artery infusion chemotherapy (HAIC), surufatinib, and tislelizumab for unresectable or metastatic …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Tract Cancer
• Gallbladder Cancer
• Intrahepatic Cholangiocarcinoma

Drugs mentioned

• HAIC (hepatic artery infusion chemotherapy)
• Surufatinib (Surufatinib)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Conditions: Carcinoma, Intrahepatic Cholangiocarcinoma | Phase 2 | Status: UNKNOWN